Pure Global
NCT05916963

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser: a Randomized Controlled Two-parallel Group Multicenter Trial With Blinding Evaluation

FIRESTONES : Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser: a Randomized Controlled Two-parallel Group Multicenter Trial With Blinding Evaluation
University Hospital, Tours·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Kidney Stone
Drug/Device/Intervention
Furosemide 40 mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University Hospital, Tours
Timeline & enrollment
Phase
Phase 3
Start date
Oct 15, 2023
End date
Jan 15, 2026
Enrollment
374 participants
Primary outcome

Stone free rate

Summary

In view of the positive results of the numerous studies conducted on forced diuresis after
 extra-corporeal lithotripsy, we chose to evaluate forced diuresis by injection of Furosemide
 associated with intravenous hydration, which has never before been the subject of a specific
 analysis.

ICD-10 classifications
Kidney dialysisSmall kidney, unspecifiedDisorder of kidney and ureter, unspecifiedInjury of kidneyUnspecified kidney failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05916963
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05916963 through Pure Global AI's free database. This Phase 3 trial is sponsored by University Hospital, Tours and is currently Not yet recruiting. The study focuses on Kidney Stone. Target enrollment is 374 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.